The potential biomarkers such as interleukin 33 (IL‐33), fetuin A, and cytokeratin 18 (CK‐18) are critical for identifying new diagnostic and therapeutic strategies for CAD, given their roles in inflammation, tissue repair, and disease progression. This evidence concerns the gene IL33 and coronary artery disorder.